Concepedia

Author

A.T. van Oosterom

Leiden University

Also Known As

A T Van Oosterom, A T van Oosterom, A. T. Oosterom, A. T. VAN OOSTEROM, A. T. Van Oosterom, A. T. van Oosterom, A.T Van Oosterom, A.T van Oosterom, A.T. VAN OOSTEROM, A.T. Van Oosterom

254

Publications

10.1K

Citations

47

H-Index

129

Concepts

All Affiliations

Leiden UniversityEuropean Organisation for Research and Treatment of CancerAntwerp University HospitalKU LeuvenThe Netherlands Cancer Institute
AV

About

A.T. van Oosterom is an author at Leiden University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

40

88

6.7K

2

Health Sciences

11

12

494

3

Natural Sciences

2

2

75

4

Engineering

1

1

15

5

Social Sciences

1

1

12

A.T. van Oosterom

×

114

Publications

9.4K

Citations

45

H-Index

YearCitations

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

Cora N. Sternberg, P.H.M. de Mulder, Jan H. Schornagel,

Journal of Clinical Oncology

2001

624

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis,

Journal of Clinical Oncology

1999

565

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Cora N. Sternberg, PHM de Mulder, Jan H. Schornagel,

European Journal of Cancer

2005

542

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson,

European Journal of Cancer

2004

442

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

René Bruno, Darcy A. Hille, A. Riva,

Journal of Clinical Oncology

1998

418

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

Ian Judson, John Radford, Martin Harris,

European Journal of Cancer

2001

382

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11

Hans Wildiers, G. Guetens, Gert De Boeck,

British Journal of Cancer

2003

328

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

J.P. Neijt, W W ten Bokkel Huinink, M E van der Burg,

Journal of Clinical Oncology

1987

312

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

G. Catimel, Jaap Verweij, Vera Mattijssen,

Annals of Oncology

1994

258

RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA

J.P. Neijt, M.E.L. van der Burg, R. Vriesendorp,

The Lancet

1984

250

Page 1